Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

16.81USD
20 Jul 2018
Change (% chg)

$1.46 (+9.51%)
Prev Close
$15.35
Open
$15.34
Day's High
$17.20
Day's Low
$15.34
Volume
38,505
Avg. Vol
39,040
52-wk High
$23.36
52-wk Low
$5.32

Chart for

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $345.83
Shares Outstanding(Mil.): 22.53
Dividend: --
Yield (%): --

Financials

  GTXI.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -1.97 -- --
ROI: -193.88 -3.65 13.18
ROE: -193.88 -5.62 15.09

Deutsche Boerse beefs up forex business with $100 million buy

BERLIN Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

May 30 2018

Deutsche Boerse beefs up forex business with $100 mln buy

BERLIN, May 30 Deutsche Boerse AG is beefing up its foreign exchange business with a $100 million deal to buy GTX's Electronic Communication Network (ECN) business from GAIN Capital Holdings Inc.

May 30 2018

BRIEF-GTx Updates Phase 2 Enobosarm Clinical Trial Results

* GTX UPDATES PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE AT 2018 AUA ANNUAL MEETING

May 18 2018

BRIEF-GTX Inc Qtrly Loss Per Share $0.62

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

Apr 09 2018

BRIEF-GTX Inc Q4 Loss Per Share $0.43

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

* GTX ANNOUNCED NEW DATA DEMONSTRATING ENOBOSARM’S POTENTIAL TO TREAT STRESS URINARY INCONTINENCE AT SUFU 2018

Mar 05 2018

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage:

Feb 22 2018

Earnings vs. Estimates